Filing Flows › Milestone Pharmaceuticals (MIST) › Q2 2026
Milestone Pharmaceuticals (MIST) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Milestone Pharmaceuticals (MIST) reported revenue of $559K for the second quarter 2026 (Q2 2026) and +135% from the quarter before.
Milestone Pharmaceuticals, Q2 2026: revenue $559K, net loss $28.6M, operating cash flow −$22.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $559K | +135% | — |
| Operating profit | −$25.6M | — | — |
| Net earnings | −$28.6M | — | — |
| Operating cash flow | −$22.7M | — | — |
What changed
Revenue was $559K in Q2 2026, up 135% from the previous quarter.
Operating costs exceeded revenue by $25.6M, an operating margin of -4585.0%. The quarter ended with a net loss of $28.6M, wider than the previous quarter's $26.1M loss.
Operating cash flow was −$22.7M. Non-cash charges added back $57K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $4.5M. Capital expenditures of $26K exceeded it, leaving free cash flow of −$22.7M.
Questions
What was Milestone Pharmaceuticals' revenue in the second quarter 2026?
Milestone Pharmaceuticals (MIST) reported revenue of $559K for the second quarter 2026 (Q2 2026) and +135% from the quarter before.